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Abstract
Cell penetrating peptides (CPPs) have been postulated to carry macromolecules across cell plasma membranes without the need of
receptors, transporters, endocytosis or any energy-consuming mechanism.
We developed an assay to study lipid bilayer permeation of CPPs. HIV-1 TAT peptides were conjugated to N-(4-carboxy-3-
hydroxyphenyl)maleimide (SAM) and incubated with Tb3 +-containing liposomes. Upon chelation of Tb3 + by an aromatic carboxylic acid,
the fluorescence of Tb3 + increases many fold. The CPP TAT(44–57)-SAM and TAT(37–53)-SAM, as a negative control, were unable to
enter liposomes consisting of phosphatidylcholine (PC) or a mix of PC, negatively charged lipids and cholesterol.
In parallel, cell entry of fluorescein-labeled TAT peptides was studied using confocal laser scanning microscopy (CLSM). TAT(44–57)-
fluorescein did not enter Madin Darby canine kidney (MDCK) cells with intact plasma membranes but accumulated at their basal side. Only
cells with impaired plasma membranes, as identified by nuclear staining with ethidium homodimer-1 (EthD-1), showed accumulation of
TAT(44–57).
Our findings change the perspectives of the potential use of TAT peptides as carriers for intracellular targeting. SAM- and fluorescein-
labeled TAT(44–57) cannot penetrate lipid bilayers and intact plasma membranes of MDCK cells, respectively.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The discovery of cell-penetrating peptides (CPPs) that
are capable to carry macromolecules across cell plasma
membranes opened new perspectives for the intracellular
targeting of peptides [1], enzymes [2,3], oligonucleotides
[4] and even larger structures such as liposomes [5] or
nanoparticles [6]. During the last few years, several CPPs
have been described. Certain CPPs seem to permeate cell
plasma membranes without the need of transporters, recep-
tors or endocytosis. Hydrophobicity is not a requirement.
The exact mechanism of cell entry is not yet identified and
is presumably different for the diverse types of peptides.
Reviews by Prochiantz [7], Lindgren et al. [8] and Fischer et
al. [9] give a comprehensive overview.
TAT peptides, a subclass of CPPs, are frequently applied
for intracellular targeting of macromolecules in in vitro and
in vivo assays. They are derived from the TAT protein, a 86-
residue transcriptional regulator of the HIV-1 virus. The
protein that contains a nuclear localization sequence has
been reported to traverse cell membranes. According to
Tyagi et al. [10], cell entry of the full-length TAT protein
follows binding to cell surface heparan sulfate proteogly-
cans. Liu et al. [11] found that cell entry is mediated by low-
density lipoprotein receptor-related protein. It has been
shown that the basic sequence TAT(48–57) is sufficient
for membrane translocation [12]. TAT peptides containing
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this sequence appear to carry proteins and fluorescent
molecules into cells in vivo or in culture [3,13,14]. Accord-
ing to previous reports, unlike full-length TAT protein, such
peptide constructs permeate cell plasma membranes inde-
pendently of classical cell entry mechanisms [9,15]. The
high content of basic amino acids in TAT(48–57) and in
other CPPs of this type are thought to constitute a trans-
duction domain.
Vive`s et al. [13] suggested an invagination of the
plasma membrane upon binding of TAT peptides to
negative charges of the lipids with the subsequent release
of the peptide into the cytoplasm. Prochiantz [7] put
forward the hypothesis that the membrane translocation
peptides derived from the Dorsophila transcription factor
Antennapedia, i.e. penetratins, induce the formation of
inverted micelles in biological membranes. Although there
is some evidence from a study with giant liposomes that
penetratin crosses lipid membranes consisting of a mix of
naturally occurring lipids [16], there is no clear proof of
translocation of such peptide conjugates across lipid
bilayers.
Today, an assay is still lacking which would allow to
unambiguously study the translocation of such peptides
across lipid bilayers. Such an assay would give useful
information on the permeation mechanism and show
whether indeed no receptor, transporter or other protein-
dependent mechanism is needed for translocation. It would
facilitate the search for new CPPs and membrane character-
istics favoring transduction.
In this study, we developed an assay that makes it
possible to clearly analyze the entry of a peptide conjugate
into the liposomal lumen. For a start, we tested two TAT
peptides: TAT(44–57), which is known for its membrane
translocation characteristics [14] and TAT(37–53), which
contains less positive charges and is not able to enter cells
even at high concentrations [13]. Both peptides were con-
jugated with N-(4-carboxy-3-hydroxyphenyl)maleimide
(SAM) and incubated with Tb3 +-containing liposomes.
Aromatic carboxylic acids such as conjugated SAM
increase the fluorescence of Tb3 + at 545 nm many fold
upon chelation when excited at a wavelength absorbed by
the aromatic system of the complex [17]. This made it
possible to investigate the permeation capacity of TAT
peptide conjugates across lipid membranes of different
compositions.
In parallel, we studied cell entry of the fluorescein-
labeled peptides on Madin Darby canine kidney (MDCK)
cell cultures using confocal laser scanning microscopy
(CLSM). The integrity of the plasma membranes was
checked with ethidium homodimer-1 (EthD-1), a stain used
for viability tests. EthD-1 is not able to cross integer plasma
membranes and displays fluorescence upon binding to
nucleic acids [18]. We could not detect any permeation of
conjugated TAT peptide across lipid bilayers. Entry into
MDCK cells was only seen in cells that were also permeable
for EthD-1.
2. Materials and methods
2.1. Materials
The peptides Cys-TAT(44 – 57) (H2N-CGISYGR-
KKRRQRRR-CONH2) and CYS-TAT(37–53) (H2N-CFIT-
KALGISYGRKKRR-CONH2) were purchased from
Eurogentec (Belgium). Peptides were >85% pure and
identity was checked by HPLC-MS by the supplier. Egg
phosphatidylcholine (PC, grade I) and other phospholipids
were delivered by Lipid Products (Nutfield, UK) and bovine
brain monosialoganglioside GM1 by Fluka. Cholesterol
and SAM were obtained from Sigma, fluorescein-5-mal-
eimide (FM), Hoechst 33342 and EthD-1 from Molecular
Probes. Terbium(III) chloride hexahydrate was purchased
from Aldrich. Methanol for liposome preparation was of
HPLC quality. All other compounds were of analytical
grade.
2.2. Peptide labeling with SAM
Peptides were incubated at a concentration of 10 mMwith
8 mM SAM in 0.16 M acetate buffer (Hac) pH 6.0 for 1 h at
room temperature. Identity and purity of the conjugated Cys-
TAT(44–57)-SAM were confirmed by C-18 reversed-phase
HPLC and subsequent MALDI-TOF analysis.
2.3. Peptide labeling with FM
Cys-TAT(44–57) and Cys-TAT(37–53) were labeled
with FM as described by Niesner et al. [14]. In brief,
100 AM FM in 10% (v/v) dimethylformamide in PBS pH
7.4 was incubated with 1 mM Cys-TAT for 60 min at
room temperature. No residual FM was detectable using
HPLC.
2.4. Liposomes
For the preparation of Tb3 +-containing liposomes,
between 20 and 100 mg lipids were dissolved together
with 0.2 mmol terbium(III) chloride in 3 ml methanol in a
250-ml round flask. The solvent was evaporated using a
rotavapor and the resulting film of lipid and terbium(III)
chloride was kept at < 10 mbar for a few hours. The dried
film was rehydrated with 2 ml water and the so formed
multilamellar liposomes were subjected to five cycles of
freeze-thawing using solid CO2 in ethanol. Unilamellar
liposomes were prepared by 10 times extrusion through
NucleoporeR polycarbonate membranes (Corning) with
200 nm pore diameter using an extruder from Lipex
Biomembranes Inc. (Vancouver, Canada) [19]. External
Tb3 + was removed on a Sephadex G-25 PD-10 desalting
column (Amersham Biosciences). The column was equili-
brated with 200 mM NaCl and 1 ml of liposome prepara-
tion was loaded and eluted with 200 mM NaCl. The first
0.2 ml of the liposome fraction were discarded, the
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following 1 ml collected for fluorescence assays. The
passage over the column resulted in a dilution factor of
about 2. The average mean sizes were between 160 and
200 nm, polydispersity factors were < 0.1 as determined
by a Zetasizer 3 (Malvern). Size distributions were
unchanged after the fluorescence assays. Extra liposomal
Tb3 + was negligible for several days when liposomes were
stored at 4 jC.
2.5. Concentration of entrapped Tb3+
To estimate the concentration of entrapped Tb3 + in the
final liposome preparation, lipids were extracted with
chloroform. Salicylic acid (SA, 25 AM) was added to the
aqueous phase and the pH adjusted to 7.0 with 20 mM 3-(N-
morpholino)propane sulfonic acid (MOPS). Fluorescence
scans were recorded between 520 and 570 nm at kex 318
nm while the sample was titrated with ethylenediaminetetra-
acetic acid (EDTA). The peak at 545 nm disappeared upon
displacement of SA from the SA/Tb3 + complex by EDTA.
The EDTA concentration at complete flattening of the
emission spectrum equaled the Tb3 + concentration in the
sample as confirmed in control experiments. Assuming a
spherical shape of the liposomes at a size of 200 nm, the
intraliposomal Tb3 + concentration was between 5 and 7
mM.
2.6. Fluorescence assays
To study membrane permeation of peptide-SAM or SA,
450 Al of liposome eluate were adjusted to pH 7.0 with 50 Al
200 mM MOPS. Between 1 and 10 Al of peptide conjugate
or SA in 0.16 M Hac pH 6.0 were added to give the final
concentrations indicated under Results. Fluorescence scans
were monitored over time between 520 and 570 nm at kex
318 nm. Temperature was kept constant at 20 jC. As a
control, 0.16 M Hac pH 6.0 was used instead of the peptide
conjugates or SA.
2.7. Data analysis
The increase in fluorescence at 545 nm DF545 nm was
calculated from the emission scans as follows:
DF545 nm ¼ F545 nm  F530 nm þ F560 nm
2
ð1Þ
where F is the fluorescence in arbitrary units at the wave-
length indicated by the index.
2.8. Cells
MDCK cells (type II) were grown in Eagle’s minimum
essential medium with Earl’s salts (EMEM) containing 10%
fetal calf serum under standard conditions [20].
 
  
Fig. 1. Entry of SA into Tb3 +-containing egg PC liposomes. Tb3 +-containing egg PC liposomes were incubated with SA and fluorescence scans were
monitored at kex 318 nm (details see text). (A) Fluorescence scans before addition of SA (no peak at 545 nm) and at different time points between 0 and 85 min
after SA addition. (B) Peak heights DF545 nm as calculated from the spectra in (A) according to Eq. (1). (C) After incubation of liposomes with SA for 85 min
(a), EDTAwas added to displace SA from extraliposomal Tb3 + (b). After EDTA addition, liposomes were lysed with Triton X-100 (c). (D) After incubation of
liposomes with SA for 50 min (a), liposomes were lysed with Triton X-100 in the absence of EDTA (b). a.u., arbitrary units.
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2.9. Confocal laser scanning microscopy
MDCK cells grown on glass cover slips for 1 or 2 days
(70–80% confluent) were washed twice with Earl’s bal-
anced salt solution (EBSS). The cultures were incubated at
37 jC as indicated with EBSS or medium without phenol
red and FCS containing peptide-FM or unconjugated FM,
2 AM Hoechst 33342 to stain DNA and/or 4 AM EthD-1 as a
probe for plasma membrane integrity. Cells were mounted
without fixation and scanned using a Zeiss CLSM 410
inverted microscope [20]. 3D multichannel image process-
ing was performed using the IMARIS software (Bitplane
AG, Switzerland).
3. Results
3.1. Permeation of SA and TAT peptide-SAM across lipid
bilayers
Peptide-SAM/Tb3 + and SA/Tb3 + complexes show
increased fluorescence at 545 nm when excited at 318 nm
as compared to the noncomplexed Tb3 +. In order to find out
whether TAT(44–57) is able to cross lipid bilayers inde-
pendently of any receptors or cellular mechanisms, Tb3 +-
containing liposomes of different lipid compositions were
incubated with Cys-TAT(44–57)-SAM and fluorescence
scans were monitored over time as described under Materi-
als and methods. To test the assay, liposome entry of SAwas
measured under the same conditions.
3.2. Fluorescence increase after SA addition to Tb3+-
containing liposomes
Fig. 1A shows the fluorescence spectra of a sample
containing Tb3 +-loaded egg PC liposomes at pH 7.0 at
different time points between 0 and 85 min after addition of
SA. The lipid concentration was about 5 mg/ml, the overall
Tb3 + concentration about 0.25 mM and the overall SA
concentration 0.05 mM. Fluorescence at 545 nm increased
by about 100 arbitrary units reaching a plateau after 1 h. The
peak height DF545 nm was calculated according to Eq. (1)
and plotted against time in Fig. 1B.
To confirm the intraliposomal localization of the fluo-
rescent SA/Tb3 + complex, EDTA was added at a final
concentration of 5 mM. EDTA is a stronger chelator for
Tb3 + than SA and displaces SA from the complex with
Tb3 + leading to an extinction of fluorescence at 545 nm
[17]. As shown in Fig. 1C, EDTA addition did not lower
DF545 nm, indicating that the fluorescence resulted from
 
  
Fig. 2. Ability of Cys-TAT(44–57)-SAM to enter Tb3 +-containing liposomes. Tb3 +-containing egg PC liposomes were incubated with 0.2 mM Cys-TAT(44–
57)-SAM or without peptide-conjugate. Fluorescence scans were monitored at kex 318 nm (details see text). (A) Fluorescence scans at different time points
between 0 and 420 min after peptide-SAM addition. (B) Peak heights DF545 nm as calculated from the spectra in (A) according to Eq. (1). Filled circles, control
without TAT-SAM; open squares, Cys-TAT(44–57)-SAM. (C) After incubation of liposomes with Cys-TAT(44–57) for 80 min (a), liposomes were lysed with
Triton X-100 (b). a.u., arbitrary units.
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intraliposomal complexes. Only upon lysis of the lip-
osomes with 1% Triton X-100 did the peak at 545 nm
completely disappear in the EDTA-containing sample
(Fig. 1C). At this concentration, the detergent has only
minor effects on the fluorescence spectra of the Tb3 +
complexes. Fig. 1D shows the spectra of a similar sample
after fluorescence has reached its maximum and after
Triton X-100 was added without EDTA. In this case,
the spectra are similar before and after lysis of the
liposomes.
Fig. 3. Cys-TAT(44–57)-FM in a CLSM permeation assay with MDCK cells. MDCK cells grown for 1–2 days on glass cover slips were incubated for 20 min
with Cys-TAT(44–57)-FM (green), Hoechst 33342 (blue) and EthD-1 (red) in EBSS at 37 jC. Cells were mounted without washing or fixation. (A–D) 1 AM
peptide-FM (10 AM total peptide); (E,F) 0.2 AM peptide-FM (2 AM total peptide). (A) x, y optical section through the center of the nuclei immediately after
mounting and (B) through a lower part of the same cells close to the cover slip. (AV,BV) and (AW,BW) x, z and y, z projections. Arrowheads indicate the positions
of the projections. (C,E) x, y optical sections through the center of the nuclei of cells with peptide-FM uptake 15 min after mounting. Co-localization of peptide-
FM and Merck 33342 appears in turquoise. (D,F) EthD-1 staining of the respective areas. Co-localization of EthD-1 and Merck 33342 appears as magenta.
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3.3. Ability of Cys-TAT(44–57)-SAM to permeate lipid
bilayers
Using the same protocol as described for SA, the abilities
of Cys-TAT(44–57)-SAM and Cys-TAT(37–53)-SAM to
permeate lipid membranes were investigated with liposomes
of different lipid compositions. Fig. 2A shows scans over
420 min in a sample containing egg PC liposomes (lipid
concentration 25 mg/ml, 0.75 mM Tb3 +) after the addition
of 0.2 mM Cys-TAT(44–57)-SAM. The respective DF545 nm
values were plotted against time and compared to a control
sample without any peptide-SAM or SA in Fig. 2B. No
Fig. 4. Cys-TAT(37–53)-FM in a CLSM permeation assay with MDCK cells. Cells were grown for 1–2 days on glass cover slips and incubated with Cys-
TAT(37–53)-FM, Merck 33342 and EthD-1 in EBSS for 20 min at 37 jC. Cells were mounted without washing or fixation and x, y scans through the center of
the nuclei were taken immediately after mounting. (A,B) 1 AM peptide-FM (10 AM total peptide); (C,D) 0.2 AM peptide-FM (2 AM total peptide). In both
cultures, EthD-1 stained >50% of total nuclei. (E,F) Cells were incubated with 1 AM FM, Merck 33342 and EthD-1 for 20 min in EBSS at 37 jC and scanned
immediately after mounting. EthD-1 stained < 5% of total nuclei.
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significant differences could be found between the DF545 nm
values of the peptide-SAM containing sample and the
control sample over time. DF545 nm increased by about 10
after 7 h due to hydroxylation of Tb3 +. Fig. 2C shows the
scans of a parallel sample after 80 min incubation with Cys-
TAT(44–57)-SAM before and after Triton X-100 addition
(1%). Upon liposome lysis, Cys-TAT-SAM was able to
complex Tb3 + ions, resulting in an increase in DF545 nm
to about 120. Similar findings were made for Cys-TAT(37–
53)-SAM in the egg PC liposome system and for Cys-
TAT(44–57)-SAM with liposomes containing 20% (mol/
mol) cholesterol, 20% phosphatidylserine, 5% oleic acid,
5% phosphatidylinositol or 1% GM1.
From this, we conclude that Cys-TAT(44–57)-SAM is
not capable to cross lipid bilayers to a significant extent. All
experiments were repeated several times at varying lipid
concentrations between 5 and 25 mg/ml and Cys-TAT(44–
57)-SAM concentrations between 0.02 and 1 mM with
reproducible results. Representative examples are shown.
3.4. Uptake of fluorescein-labeled TAT peptides into MDCK
cells
In order to study uptake of TAT peptides into cultured
cells using CLSM, Cys-TAT peptides were conjugated with
FM as described under Materials and methods. MDCK cells
were incubated for 20 min at 37 jC with EBSS containing
the labeled Cys-TAT peptides or unconjugated FM as a
control together with Hoechst 33342 to stain DNA and
EthD-1 to identify cells with impaired plasma membranes.
Final total peptide concentrations were either 2 or 10 AM, as
indicated, of which 10% were labeled with FM. CLSM
scans were taken from preparations without fixation.
No entry of Cys-TAT(44–57)-FM into cells with integer
plasma membranes was observed at both concentrations.
Only cells permeable for EthD-1 were also permeable for
TAT(44–57)-FM. Fig. 3A shows an optical section (x, y)
taken through the center of the nuclei of a cell monolayer
incubated with 1 AM Cys-TAT(44–57)-FM (10 AM total
Fig. 5. Plasma membrane integrity of MDCK cells after TAT(44–57)-FM incubation. Cells were grown for 1–2 days on glass cover slips and incubated with 1
AM Cys-TAT(44–57)-FM (10 AM total peptide) and Merck 33342 in medium without FCS for 2 h at 37 jC. Cells were washed and incubated with EthD-1 for
further 20 min at 37 jC either immediately (A,B) or after 20 min recovery at 37 jC in medium without FCS (C,D). After washing, cells were mounted without
fixation and x, y optical sections were taken through the center of the nuclei. The micrographs focus on areas with peptide uptake. In all cultures, green/red
nuclei accounted for < 5% of total nuclei.
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peptide). The preparation was immediately scanned after
mounting in incubation medium. Neither EthD-1 nor pep-
tide-FM are found in the nuclei or the cytoplasm of these
cells. An optical section through the lower part of the cell
layer (Fig. 3B) reveals an accumulation of Cys-TAT(44–57)-
FM. This localization of peptide close to the cover slip is well
recognized in the x, z and y, z optical sections in Fig. 3AV, AW,
BV and BW. Findings were similar with 0.2 AMCys-TAT(44–
57)-FM (2 AM total peptide) and with cultures that were
washed before mounting in EBSS or medium (not shown).
About 15min after mounting at room temperature, EthD-1
started to enter part of the cells at both peptide concen-
trations tested, indicating that the integrity of the plasma
membranes became compromised. At the same time, Cys-
TAT(44–57)-FM accumulated in the nuclei of these cells.
Intact cells were still free of Cys-TAT(44–57)-FM. Fig.
3C–F illustrates foci of compromised cells with EthD-1
and peptide-FM staining.
In preparations with Cys-TAT(37–53)-FM, >50% of the
cells were permeable to EthD-1 immediately after mounting
(Fig. 4). Peptide-FM was found in the nuclei as well as in
the cytoplasm of these cells. Control cultures incubated with
1 AM FM, EthD-1 and Hoechst 33342 contained less than
5% EthD-1 stained nuclei. No FM was detectable within
these cells or at the cell borders. Fig. 4E/F shows optical
sections through the center of the nuclei focusing on an area
containing EthD-1 stained nuclei.
To test whether the observed plasma membrane perme-
ability to Cys-TAT(44–57)-FM and EthD-1 under the above
conditions was induced by the peptide or due to nonideal
conditions after mounting, cells were incubated for 2 h with
1 AM Cys-TAT(44–57)-FM (10 AM total peptide). All
incubations and washing steps were carried out in medium
without FCS at 37 jC. After peptide incubation, cultures
were washed and incubated with EthD-1 for 20 min. After
further washing, cells were mounted and optical sections
through the center of the nuclei were immediately taken. No
substantial peptide uptake was observed under these con-
ditions. Less than 5% of total nuclei were stained with Cys-
TAT(44–57)-FM. The same nuclei were positive for EthD-1
uptake. Fig. 5A,B illustrates a cell culture area containing
stained cells. The result was the same after incubation with
peptide for 4 h (not shown). The cultures contained a similar
percentage of EthD-1 stained cells as control cultures treated
with 1 AM FM and EthD-1 (see Fig. 4F). To confirm that
cells displaying TAT uptake were irreversibly permeable to
EthD-1, cultures were incubated for 20 min in fresh medium
at 37 jC after incubation with peptide and before EthD-1
was added. Findings were the same as without the recovery
phase (Fig. 5C,D).
4. Discussion
Our findings put the perspectives for TAT peptides as
carriers for intracellular targeting into a new light. The TAT
peptide conjugates were neither able to cross pure lipid
bilayers nor did they enter MDCK cells with integer plasma
membranes.
Using a novel assay that allows to visualize entry of
aromatic carboxylic acids into liposomes, we could clearly
demonstrate that Cys-TAT(44–57) is not able to carry the
aromatic carboxylic acid SAM into Tb3 +-containing lip-
osomes, independently of the presence or absence of neg-
atively charged lipids in the membrane. This contradicts the
hypothesis that TAT peptides permeate lipid membranes
without the need of any other mechanisms such as ATPases,
carriers, receptors or endocytosis.
The liposomal assay presented in this study is broadly
applicable. The only prerequisite is that the studied
molecule either contains an aromatic carboxylic acid or
that such a moiety can be conjugated to it without
changing the membrane permeation properties of the
molecule.
Tb3 + is an ideal intraliposomal partner for the gen-
eration of fluorescence. Tb3 +-loaded liposomes were used
together with liposomes containing dipicolinic acid in
liposome fusion assays [21]. Due to its hydrophilicity
and high charge density, Tb3 + is localized in the lip-
osomal lumen and neither accumulates in the lipid bilayer
nor leaks out of the liposomes. Therefore, fluorescence
only occurs upon liposome entry of the molecule under
study and not on accumulation in or binding to the
membrane.
Complementary studies with living cells in the CLSM
showed that no plasma membrane permeation occurred
with intact MDCK cells. Cys-TAT(44–57)-FM was not
observed in the nuclei or the cytoplasm of living cells
after up to 4 h of peptide incubation in medium at 37 jC.
Only cells permeable for EthD-1, a marker for plasma
membrane impairment, showed uptake and accumulation
of Cys-TAT(44–57)-FM in the nuclei. Cells that had taken
up the peptide-FM remained permeable to EthD-1 also
after 20 min of recovery at 37 jC. In medium at 37 jC,
the number of compromised cells was similar to the
number of EthD-1 stained cells in a control culture
incubated with FM and EthD-1. However, in EBSS at
room temperature (conditions after mounting), both the
peptide-FM and EthD-1 started to enter a higher number
of cells. From this, we conclude that only deteriorating
cells are susceptible to TAT(44–57) peptide entry. In
contrast to TAT(44–57), TAT(37–53) had toxic effects
on the MDCK cells already at a concentration of 2 AM.
Also, Vive`s et al. [13] found higher toxicity for this
peptide as compared to TAT(44–57) in cultures of HeLa
cells using an MTT test.
Our observations that TAT(44–57)-FM is not capable
to permeate intact plasma membranes of MDCK cells are
in line with findings from Violini et al. [22]. They fully
agree with our own results from the liposomal approach,
the Tb3 + assay. There is no evidence that TAT peptides
could traverse integer biological membranes by an
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unspecific energy-independent mechanism as previously
postulated. The discrepancies between these findings and
reports on cellular uptake of TAT peptides using other
cell lines [13–15] would rather favor the hypothesis of a
more specific cell line-dependent mechanism.
It became obvious from our own studies and from
investigations by Lundberg and Johansson [23] that micro-
scopic investigations on cellular uptake of CPPs are prone
to artifacts, be it from fixation, which is known to
produce leakiness, or be it due to the deterioration of
unfixed cells in mounted preparations. Furthermore, care
has to be taken to differentiate between uptake of peptides
into the cells and accumulation at the cell surface. The
latter could eventually act as a deposit that enters deteri-
orating cells after mounting. Using different incubation
conditions and by testing the integrity of the cells with
EthD-1, we could clearly distinguish between living and
deteriorating cells. Analysis of the CLSM data for co-
localization of peptide-FM with DNA, i.e. Merck 33342
staining, and the generation of optical z sections allowed
us to discriminate between nuclear peptide accumulation
and peptide deposition at the interface between cells and
cover slip.
Unambiguous cell entry has been shown with larger
constructs, e.g. fluorescently labeled TAT–protein conju-
gates. In this case, a vesicular staining of cells is found
[14,24], indicating that larger constructs possibly enter by
the endocytotic pathway.
The novel liposome assay, together with CLSM studies,
will now allow us to check further CPPs for their ability to
cross lipid bilayers and to enter intact cells.
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